-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Immix Biopharma, Lowers Price Target to $19

Benzinga·08/11/2026 15:56:06
语音播报
Morgan Stanley analyst Judah Frommer maintains Immix Biopharma (NASDAQ:IMMX) with a Overweight and lowers the price target from $20 to $19.